Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

mRNA-1405

RNA therapy

mRNA-1405 is one of 21 biologic programs targeting Gastroenteritis. It is currently in development.

1

Indications

1

Total Trials

1

Active Trials

20

Competitors

Pipeline

Status by Indication[3][1]

Indication

GastroenteritisActive, not recruiting

GastroenteritisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

32 competitors in Gastroenteritis

#DrugCompanyPhaseTrials

Zofran

Cipro

Reglan

IIstituto Clinico Humanitas

Hyoscine-N-Butylbromide

Boehringer Ingelheim

Dimenhydrinate

SSt. Justine's Hospital

Rotarix ™

Domperidone

Johnson & Johnson

Prulifloxacin

Xolair

Papaverine

WWestern Galilee Hospital-Nahariya

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Recruiting

Gastroenteritis

NCT05992935

Clinical

Trials by Indication[1]

Gastroenteritis1 trial

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

Recruiting· Moderna logo

Moderna·Phase 1/2·NCT05992935·1,405 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for mRNA-1405. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mRNA-1405 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mRNA-1405. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Moderna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Company: Moderna

Related News